Progyny (NASDAQ:PGNY) EVP Sells $15,022.92 in Stock

by · The Cerbat Gem

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) EVP Allison Swartz sold 599 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.08, for a total value of $15,022.92. Following the transaction, the executive vice president directly owned 82,378 shares in the company, valued at approximately $2,066,040.24. The trade was a 0.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

  • On Wednesday, June 3rd, Allison Swartz sold 1,199 shares of Progyny stock. The stock was sold at an average price of $25.02, for a total value of $29,998.98.

Progyny Stock Performance

PGNY stock traded up $0.38 during mid-day trading on Friday, reaching $25.86. The company had a trading volume of 1,207,696 shares, compared to its average volume of 1,553,521. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 33.58, a price-to-earnings-growth ratio of 1.33 and a beta of 1.03. The firm has a fifty day simple moving average of $20.42 and a 200 day simple moving average of $22.27. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $28.75.

Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, analysts predict that Progyny, Inc. will post 1.12 earnings per share for the current year.

Progyny announced that its board has initiated a share repurchase plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of analyst reports. Truist Financial increased their price target on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, Canaccord Genuity Group raised Progyny from a “hold” rating to a “buy” rating and increased their price target for the company from $19.00 to $30.00 in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.67.

Get Our Latest Stock Analysis on PGNY

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new position in shares of Progyny in the 4th quarter valued at about $25,000. Federated Hermes Inc. increased its holdings in shares of Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after acquiring an additional 819 shares during the last quarter. Hantz Financial Services Inc. grew its stake in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares during the last quarter. Quarry LP grew its stake in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after buying an additional 3,427 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in Progyny during the 2nd quarter worth approximately $77,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

Further Reading